Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Travel grant France

Reference number
Coordinator CellProtect Nordic Pharmaceuticals AB
Funding from Vinnova SEK 15 000
Project duration November 2017 - January 2018
Status Completed
Venture Travel grant
Call Travel grant for building international consortia

Purpose and goal

CellProtect Nordic Pharmaceuticals (CPNP) is seeking partnering opportunities for the further clinical development of its platform technology, CellProtect, an Advanced Medicinal Product based on autologous ex vivo expanded Natural Killer cells with restored cytotoxic activity. CPNP has been granted Orphan Drug Designation for the treatment of Multiple Myeloma from the EC and are planning to advance the clinical development of Cellprotect and reach the market via accelerated/conditional approval.

Expected results and effects

Communicate the CellProtect project and its recent successes and the clinical development plan forward. Make CellProtectNordicPharmaceuticals visible. Identification of potential stakeholders and partners. Networking with potential collaborators.

Planned approach and implementation

CPNP was represented by Karin Mellström CEO and Marcus Lagerlöf BD and responsible for the financing procurement process. The Company activly participated in a pitch session and also in several sucessful pre-booked one to one partnering meetings. Therse meeting are activily followed-up and contribute significantly to CPNPs financing procuremnet process.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2017-05133

Page statistics